1. Home
  2. Directory
  3. North Carolina
  4. Morrisville
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1104489657

HANNA YAYNSHET NIGATU
Prescription History 1104489657
Internal Medicine - Infectious Disease in Morrisville, NC

NPI Status: Active since April 19, 2019

Contact Information

5221 PARAMOUNT PKWY STE 220
MORRISVILLE, NC
ZIP 27560
Phone: (443) 822-1853

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for HANNA YAYNSHET NIGATU, an active Infectious Disease specialist practicing in Morrisville, NC. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 95 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 28 claims alone.

Medication Index

B
O
P
S
T
No matching medications currently found on file.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 840
NC State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills94.8
Peer Average Days Supply2,838
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.9% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116,057.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,144.92

State Avg Cost Per Claim

$3,899.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Odefsey

Generic Formulation: Emtricitab/Rilpiviri/Tenof AlaSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
NC State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills37.2
Peer Average Days Supply1,110
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.9% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47,965.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,689.68

State Avg Cost Per Claim

$3,526.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 different medications: emtricitabine, rilpivirine, and tenofovir alafenamide. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Emtricitabine and tenofovir alafenamide belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Rilpivirine belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Emtricitabine/rilpivirine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Prezcobix

Generic Formulation: Darunavir/CobicistatSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
NC State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.3
Peer Average Days Supply1,019
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,144.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,558.57

State Avg Cost Per Claim

$2,426.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: darunavir and cobicistat. Darunavir belongs to a class of drugs known as protease inhibitors. Cobicistat is used to increase (boost) the levels of darunavir. Darunavir/cobicistat is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 510
NC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply411
Conservative Utilization

This provider writes prescriptions for this formulation 28.0% less frequently than the standard regional baseline metric for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $372.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.67

State Avg Cost Per Claim

$6.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 750
NC State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills54.9
Peer Average Days Supply1,620
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.7% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $56,956.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,278.25

State Avg Cost Per Claim

$2,269.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like HANNA YAYNSHET NIGATU provides transparency into local medical care patterns within Morrisville, NC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.